ABSTRACT
Non-varicose upper gastrointestinal bleeding is one of the common causes of hospitalization with high mortality and morbidity. The aim of this study was to investigate the effect of Octreotide in treating non-varicose upper gastrointestinal bleeding. In this clinical trial with IRCT: 1361, patients with gastrointestinal bleeding, with neither gastrointestinal varices nor hepatic failure, were enrolled into two groups designated respectively as A and B. Patients in group A received routine treatment. In group B, in addition to routine treatment, patients received 50 microg bolus Octreotide and 25 microg/h infusions. For comparison between the two groups the difference hemoglobin at arrival time, hemoglobin the time of discharge, length of stay in the emergency department, required blood transfusion, the recurrence rate of bleeding and death rate were assessed. In this study, 80 patients in both groups were examined. There was no difference in age and sex between two groups. Hemoglobin on arrival in the two groups showed no significant difference, but hemoglobin level was different at the discharge time. Our study showed no significant difference between two groups about average of received pack Cell. Our results demonstrated that length of stay at emergency department, decreased hemoglobin and bleeding recurrence rate had no significantly difference between two groups. The result showed that Octreotide can't add an extra value for treating upper varicosdee gastrointestinal bleeding